Myriad Genetics (MYGN) Equity Average (2016 - 2025)
Myriad Genetics (MYGN) has disclosed Equity Average for 15 consecutive years, with $370.4 million as the latest value for Q4 2025.
- On a quarterly basis, Equity Average fell 48.3% to $370.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $370.4 million, a 48.3% decrease, with the full-year FY2025 number at $534.6 million, down 27.97% from a year prior.
- Equity Average was $370.4 million for Q4 2025 at Myriad Genetics, down from $380.4 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $968.2 million in Q4 2021 to a low of $370.4 million in Q4 2025.
- A 5-year average of $773.7 million and a median of $778.4 million in 2023 define the central range for Equity Average.
- Peak YoY movement for Equity Average: increased 9.21% in 2022, then plummeted 48.32% in 2025.
- Myriad Genetics' Equity Average stood at $968.2 million in 2021, then fell by 6.92% to $901.2 million in 2022, then fell by 18.63% to $733.3 million in 2023, then fell by 2.3% to $716.4 million in 2024, then tumbled by 48.3% to $370.4 million in 2025.
- Per Business Quant, the three most recent readings for MYGN's Equity Average are $370.4 million (Q4 2025), $380.4 million (Q3 2025), and $546.5 million (Q2 2025).